BridgeMD
Tests treatment safety and results for Advanced Solid Tumors
Official title A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
ClinicalTrials.gov ID: NCT06818643
What this study is testing
What is MK-3120?
MK-3120 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for advanced solid tumors.
Also referred to as SKB410.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments
- If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART)
- If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have...
- If hepatitis C virus (HCV) infected, must have undetectable HCV viral load
You likely can't join if
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
- Has uncontrolled significant cardiovascular disease or cerebrovascular disease
- Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays...
- Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
- Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 2 years
See the full eligibility criteria
- Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments
- If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART)
- If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
- If hepatitis C virus (HCV) infected, must have undetectable HCV viral load
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
- Has uncontrolled significant cardiovascular disease or cerebrovascular disease
- Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
- Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
- Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 2 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active infection requiring systemic therapy, with exceptions
- History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has HBV or HCV infection
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Miami, Florida, United States
- Hackensack, New Jersey, United States
- Austin, Texas, United States
- Houston, Texas, United States
- Irving, Texas, United States
- Richmond, Virginia, United States
- Santiago, Region M. de Santiago, Chile
- Beijing, Beijing Municipality, China
- Chongqing, Chongqing Municipality, China
- Changsha, Hunan, China
- Changchun, Jilin, China
- Chengdu, Sichuan, China
- Marseille, Bouches-du-Rhone, France
- Rennes, Ille-et-Vilaine, France
- Lille, Nord, France
- Villejuif, Val-de-Marne, France
- Haifa, Israel
- Petah Tikva, Israel
- Ramat Gan, Israel
+ 20 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Miami, Florida, United States; Hackensack, New Jersey, United States; Austin, Texas, United States; Houston, Texas, United States; Irving, Texas, United States and 34 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.